Half-Year 2022 Financial and Clinical Trials Update slide image

Half-Year 2022 Financial and Clinical Trials Update

HER2+ franchise: High efficacy and safety bar established in eBC Perjeta conversion rate at 27% in early launch countries 50% Phesgo with strong global launch Global Perjeta conversion rate* Continuing to build on existing standard of care Ph III (heredERA) in 1L HER2+/ER+ mBC 40% 30% 20% 10% 0% 27% Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 ER+/HER2+ ABCa Previously untreated in the advanced setting Induction Randomization Maintenance Arm A PHESGOC Min. 4 cycles PHESGO +Taxane (4-6 cycles) of induction Minimum SD LVEF of ≥50% R 1:1 PD PHESGO Arm Bd Giredestrante Long-term follow-up Roche • Phesgo SC significantly cuts healthcare costs and resource use • HER2+/HR+ BC with distinctive disease biology • Perjeta conversion rate reaches 27% in early launch countries • P+H in eBC (APHINITY): 8-year follow up data presented at ESMO Virtual Plenary showing a 28% reduction in the risk of recurrence or death for high risk, lymph-node positive patients ⚫ Ph III (heredERA) of Phesgo + giredestrant in 1L HER2+/ER+ mBC started enrollment in Q2 2022, and aims to improve: efficacy by comprehensive blockade of both HER2 and ER pathways • treatment related QOL, with a patient centric regimen P=Perjeta; H-Herceptin; HR-Hormone receptor; HER2-Human epidermal growth factor receptor 2; BC=Breast cancer; eBC-Early breast cancer; mBC=Metastatic breast cancer; ER-Estrogen receptor; IV-Intravenous; SC=Subcutaneous; QoL-Quality of life; SD-Stable disease; LVEF=Left ventricular ejection fraction; PD-Progressive disease; *Perjeta conversion rate is based on volumes (vials) and includes all launch countries after the 2nd quarter after the launch (17 countries); Phesgo in collaboration with Halozyme; ESMO-European Society for Medical Oncology 22
View entire presentation